All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the European School of Haematology (ESH) 2nd Translational Research Conference: Acute Lymphoblastic Leukaemia, the ALL Hub spoke to Elias Jabbour, MD Anderson Cancer Center, Houston, US. We asked, How has targeted therapy impacted the prognosis for patients with a high disease burden in ALL?
How has targeted therapy impacted the prognosis for patients with a high disease burden in ALL?
In this video, Jabbour discusses the impact of targeted therapies for adult patients with ALL, including tyrosine kinase inhibitors, monoclonal and conjugated antibodies, bispecific engagers, and chimeric antigen receptor (CAR) T cells. He believes targeted therapies significantly improve the outcomes of patients with high disease burden.
Anti-CD22 CAR T-cell potency and toxicity is affected by CD4/CD8 T-cell selection
Despite recent advances made with CD19-targeted immunotherapies, there are limited effective treatment options for patients with B-cell acute lymphoblastic leukemia...
What is new for CAR T-cell therapy for adult patients with ALL?
During the 3rd European CAR T-cell Meeting, the ALL Hub spoke to Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, What is new for CAR T-cell therapy for adult patients with ALL?
Subscribe to get the best content related to ALL delivered to your inbox